Comparative study of mini chromosome maintenance deficient-5 and urine cytology as urinary biomarkers for the diagnosis of bladder cancer
DOI:
https://doi.org/10.18203/2349-2902.isj20254324Keywords:
Bladder cancer, Voided urine cytology, MCM5, Cystoscopy, BiopsyAbstract
Background: Bladder cancer is the 9th most common cancer worldwide and the 13th most common cause of death accounting for 145,000 deaths worldwide. In Sokoto, Nigeria, bladder cancer is the most common male cancer and the area is endemic for schistosomal infestation. Mini chromosome maintenance deficient 5 (MCM5) is a potential urinary biomarker for bladder cancer diagnosis, study of this biomarker is essential to compare its effectiveness in diagnosing bladder cancer with voided urine cytology.
Methods: Patients presenting at the urology out-patient clinic of the Usmanu Danfodiyo University Teaching Hospital, Sokoto between February 2,2018 and February 1, 2019 with clinical and radiological suspicion of bladder cancer who met the inclusion criteria and gave informed consent were recruited for the study. Data analysis was done using IBM statistical package for the social sciences (SPSS) version 20.0 computer software package and diagnostic validity indicators of each marker was computed.
Results: A total of 65 patients were recruited into the study with a mean age of 51.9 years and standard deviation of ±14.7. The male to female ratio was 6:1. The commonest histological type of bladder cancer seen was squamous cell carcinoma (70.8%). The biomarker MCM5 was found to be more sensitive in diagnosing squamous cell carcinoma than the other histological types of bladders.
Conclusion: The biomarker MCM5 is more sensitive but less specific than voided urine cytology in the diagnosis of bladder cancer. Also, MCM5 is more sensitive in diagnosing squamous cell carcinoma than other histological types of bladder cancer.
References
Lopez-Beltran A. Bladder cancer: Clinical and pathological profile. Scand J Urol Nephrol Suppl. 2008;218:95-109.
Malami SA, Umar HP, Bawa AA, Mungadi IA, Abdullahi AD, Ayuba D, et al. A descriptive retrospective study of pattern of malignant diseases in Sokoto, Northwestern Nigeria (1999–2004). J Med Sci. 2007;7:1033-8.
Mungadi IA, Malami SA. Urinary bladder cancer and schistosomiasis in Northwestern Nigeria. West Afr J Med. 2007;26:226-9.
Aghaji AE, Mbonu OO. Bladder tumours in Enugu, Nigeria. Br J Urol. 1989;64:399-402.
Obafunwa JO. Histopathological study of vesical carcinoma in Plateau State, Nigeria. Eur J Surg Oncol. 1991;17:489-91.
Thomas JO, Onyemenem TN. Bladder carcinoma in Ibadan, Nigeria: A changing trend. East Afr Med J. 1995;72:49-50.
Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: 2011 update. Eur Urol. 2011;59:997-1008.
Almallah YZ, Rennie CD, Stone J, Lancashire MJ. Urinary tract infection and patient satisfaction after flexible cystoscopy and urodynamic evaluation. Urology. 2000;56:37-9.
Kristen LG, Badrinath K. Urinary markers for bladder cancer. AUA Update Series Lesson 33. 2007;26:326-35.
Bell SP, Dutta A. DNA replication in eukaryotic cells. Annu Rev Biochem. 2002;71:333-74.
Stoeber K, Halsall I, Freeman A, Swinn R, Doble A, Morris L, et al. Immunoassay for urothelial cancers that detects DNA replication protein MCM5 in urine. Lancet. 1999;354:1524-5.
Cordon-Cardo C, Reuter VE, Lloyd KO, Sheinfeld J, Fair WR, Old LJ, et al. Blood group related antigens in human urothelium: Enhanced expression of precursor, LeX and LeY determinants in urothelial carcinoma. Cancer Res. 1988;48:4113-20.
Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl. 2008;218:12-20.
Stoeber K, Swinn R, Prevost AT, de Clive-Lowe P, Halsall I, Dilworth SM, et al. Diagnosis of genitourinary tract cancer by detection of minichromosome maintenance protein 5 in urine sediments. J Natl Cancer Inst. 2002;94:1071-9.
Burling K, Dudderidge T, Halsall I, Kelly J, Leung H, Okoturo O, et al. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of MCM5 and nuclear matrix protein 22. PLoS One. 2012;7:e40305.
Avwioro OG. Histochemistry and tissue pathology: Principles and techniques. 1st edition. Ibadan: Claverianum Center. 2002.
Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, et al. Bladder tumour markers beyond cytology: International Consensus Panel on bladder tumour markers. Urology. 2005;66:35-63.
Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol. 2011;60:484-92.
Volpe A, Racioppi M, D'Agostino D, Cappa E, Gardi M, Totaro A, et al. Bladder tumour markers: A review of the literature. Int J Biol Markers. 2008;23:249-61.
Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumour markers in the diagnosis of primary bladder cancer: A systematic review. J Urol. 2003;169:1975-82.
Muhammad AS, Mungadi IA, Ndodu ED, Kalayi GD. Performance of urinary survivin as a non-invasive molecular marker of bladder carcinoma in a schistosomiasis-endemic area. Ghana Med J. 2018;52:74-8.
Leyh H, Marberger M, Conort P, Sternberg C, Pansadoro V, Pagano F, et al. Comparison of the BTA test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol. 1999;35:52-6.
David PW. Urothelial tumors of the bladder. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, editors. Campbell-Walsh Urology. Philadelphia: Saunders Elsevier. 2012;10:2311-29.
Downloads
Published
How to Cite
Issue
Section
